Diagnostic Hybrids

Diagnostic HYBRIDS, Inc. develops, manufactures, and sells cellular and molecular diagnostic kits for various applications in detecting respiratory diseases, herpes infections, thyroid function, and other disease markers. The company offers the D3 FastPoint L-DFA Influenza A/B Virus Identification Kit, which can identify Influenza A and B viruses from patient specimens within 30 minutes. It also develops and commercializes genetically engineered cell assay products for the pharmaceutical and biotechnology industries, focusing on drug analysis and products measuring drug clearance and antiviral intervention with drugs and vaccines. Additionally, the company provides a range of products for specimen collection, specimen transport, multivirus cell culture amplification, and detection of sensitive and specific viruses using monoclonal antibody kits and reagents. Moreover, it offers solutions for detecting respiratory, herpes, chlamydia, and enteroviruses; monolayer cell line products for diagnosing and detecting viruses that cause human diseases; Clostridium difficile toxins; flocked swabs and UTM; and media and supplements, including prepared media, saline solutions, antibiotic solutions, and trypsin solutions. Furthermore, the company provides products and services for non-diagnostic applications, including in vitro toxicology and metabolism products and services such as primary hepatocytes and hepatocyte-based assays. It also supports educational programs for Influenza A, Influenza B, RSV, MPV, adenovirus, and parainfluenza viruses 1, 2, and 3 through direct speaker programs, educational grants, and internet-based educational programs.